CB5138-3

Key Highlights – CB5138-3

We are developing CB5138-3 to treat IPF and are evaluating the impact of CB5138 Analogs on a variety of other chronic fibrotic conditions. CB5138-3 has been shown to:

  • Decrease expression of fibrosis biomarkers in co-cultures of lung cells and fibroblasts.*
  • Decrease Ashcroft fibrosis score and lymphocytes in lung fluid after 21 days in prophylactic mouse model.*
  • Demonstrate positive effects on all study outcomes in a therapeutic mouse model, including significantly reduced lung fibrosis as evidenced by decreases in the Ashcroft Score, fibrosis-related changes in lung weight, collagen deposition in lung tissue and collagen secretion into lung fluid.
  • Demonstrate significant reductions in lung fluid levels of a variety of pro-inflammatory cytokines and inflammatory cells in a therapeutic mouse model.

*This preclinical activity was demonstrated in earlier CB5138 Analogs

Why CB5138-3?

Current treatment options for IPF are limited and poorly tolerated due to significant gastrointestinal and skin toxicity. Our CB5138-3 product candidate has impressive preclinical results, with anti-fibrotic properties comparable to those seen with nintedanib (the active ingredient in OFEV®), one of the two currently approved drugs for IPF. We believe CB5138-3 has the potential to provide a better safety profile than currently approved IPF drugs and could provide important clinical and commercial advantages over current standard of care.

Posters & White Papers

Broad Effects – Specific Mechanism Under Investigation

We have demonstrated through multiple preclinical studies that this family of peptides has broad anti-fibrotic and anti-inflammatory effects. Currently, CohBar scientists are exploring a variety of potential molecular targets to better elucidate the specific mechanism of action for CB5138-3.

Clinical Development

We are currently in the process of conducting IND-enabling studies, with the goal of filing an IND in the second half of 2023 and initiating our First-in-Human trial for CB5138-3 shortly thereafter.